ArticleProceedings of the National Academy of Sciences of the United States of America2002
Subnuclear distribution of topoisomerase I is linked to ongoing transcription and p53 status.
Article in Proceedings of the National Academy of Sciences of the United States of America, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 51 citations in OpenAlex.
- A concept of dual-responsive prodrugs based on oligomerization-controlled reactivity of ester groups: an improvement of cancer cellsRSC medicinal chemistry · 2024Article
- Expression and Purification of Vaccinia Virus DNA Topoisomerase IB Produced in the Silkworm-Baculovirus Expression System.Molecular biotechnology · 2019Article
- Dynamics of tobacco DNA topoisomerases II in cell cycle regulation: to manage topological constrains during replication, transcription and mitotic chromosome condensation and segregation.Plant molecular biology · 2017Article
- Camptothecin resistance is determined by the regulation of topoisomerase I degradation mediated by ubiquitin proteasome pathway.Oncotarget · 2017Article
- Poly(ADP-ribose) polymers regulate DNA topoisomerase I (Top1) nuclear dynamics and camptothecin sensitivity in living cells.Nucleic acids research · 2016Article
- Nucleolar control of p53: a cellular Achilles' heel and a target for cancer therapy.Cellular and molecular life sciences : CMLS · 2014Review
- Emerging roles of the nucleolus in regulating the DNA damage response: the noncanonical DNA repair enzyme APE1/Ref-1 as a paradigmatical example.Antioxidants & redox signaling · 2014Review
- Nucleolar AATF regulates c-Jun-mediated apoptosis.Molecular biology of the cell · 2012Article
- Decreased catalytic function with altered sumoylation of DNA topoisomerase I in the nuclei of scleroderma fibroblasts.Arthritis research & therapy · 2011Article
- Role of a tryptophan anchor in human topoisomerase I structure, function and inhibition.The Biochemical journal · 2008Article
- The novel PIAS-like protein hZimp10 is a transcriptional co-activator of the p53 tumor suppressor.Nucleic acids research · 2007Article
- Topoisomerase II, not topoisomerase I, is the proficient relaxase of nucleosomal DNA.The EMBO journal · 2006Article
- Human DNA topoisomerase I: relaxation, roles, and damage control.Chromosoma · 2005Review
- Residues 190-210 of human topoisomerase I are required for enzyme activity in vivo but not in vitro.Nucleic acids research · 2003Article
- The tumor suppressor protein p53 stimulates the formation of the human topoisomerase I double cleavage complex in vitro.Oncogene · 2002Article
- Stress-dependent nucleolin mobilization mediated by p53-nucleolin complex formation.Molecular and cellular biology · 2002Article
Corrections and comments
- Erratum issued
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The nonconserved, hydrophilic N-terminal domain of eukaryotic DNA topoisomerase I (topo I) is dispensable for catalytic activity in vitro but essential in vivo. There are at least five putative nuclear localization signals and a nucleolin-binding signal within the first 215 residues of the topo I N-terminal domain. We have investigated physiological functions of the topo I N-terminal domain by fusing it to an enhanced green fluorescent protein (EGFP). The first 170 residues of the N-terminal domain allow efficient import of chimeric proteins into nuclei and nucleoli. The nucleolar localization of this protein does not depend on its interaction with nucleolin, whereas ongoing rDNA transcription clearly is crucial. Immunoprecipitation experiments reveal that the topo I N terminus (topoIN)-EGFP fusion protein associates with the TATA-binding protein in cells. Furthermore, DNA damage results in extensive nuclear redistribution of the topoIN-EGFP chimeric product. The redistribution is also p53-dependent and the N terminus of topo I appears to interact with p53 in vivo. These results show that the topo I localization to the nucleolus is related to the p53 and DNA damage, as well as changes in transcriptional status. Nucleolar release of topo I under conditions of cellular duress may represent an important, antecedent step in tumor cell killing by topoisomerase active agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.